查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198657

移植市场增长、趋势、COVID-19 的影响和预测 (2023-2028)

Transplantation Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计移植市场在预测期内（2022-2027 年）的复合年增长率为 9.9%。

市场增长的主要驱动力是对新型组织移植产品和器官移植治疗器官衰竭的需求不断增长。根据发表在 Current Transplantation Reports 上的一项题为“实体器官移植中 COVID-19 的诊断测试”的研究:根据 "Current Clinical Application and Future Strategies" ，2020 年 10 月，实体器官移植将受到 COVID-19 疫情的影响，包括供体和受体的适宜性、移植后感染和感染预防。此外，根据 2022 年 5 月发表在American Journal of Critical Care上的题为 "Epidemiology of Organ Failure Before and During COVID-19 Pandemic Surge Conditions" 的研究，肾衰竭是大流行期间入院时最常见的器官衰竭。衰竭是医院中最常见的器官衰竭。在 SARS-CoV-2 阳性组中，与大流行前相比，呼吸衰竭增加了 231%。因此，随着器官衰竭的增加，移植需求在预测期内将会增加。

此外，全球对组织器官移植，尤其是肾臟、心臟、肝臟和肺移植的需求非常高。器官衰竭是由多种因素引起的，包括不良饮食、过度饮酒、缺乏运动和药物滥用。因此，对植入式产品的需求预计将很快增加。器官捐献的增加是研究中市场增长的最重要因素之一。根据器官获取组织协会（AOPO）2021 年 1 月公布的数据，2020 年有超过 12500 人捐献了一个或多个器官，比上一年增加了 6%。此外，2020年已故器官捐献者数量达到3.65万多件，比上年增长约2%。这些摘取的器官挽救了超过33,000条生命，连续第七年超过上年。心血管死后捐赠（DCD）也有所增加，超过 3,000 人，同比增长 18%。

此外，癌症、心臟和肾臟疾病等慢性病患病率的增加正在推动市场增长。例如，国际肾脏病学会 (ISN) 和国际肾臟基金会联合会 (IFKF) 联合倡议的 2020 年 3 月世界肾臟日发布的数据表明，肾臟疾病影响着全球约 8.5 亿人。此外，根据全球癌症观察站发布的全球185个国家36种癌症的发病率和死亡率估算的Globocan 2020报告显示，2020年将有19,292,789名新确诊癌症患者，19,292,789人将死于癌症. 估计约为 9,958,133。

此外，主要市场参与者的产品发布以及併购等市场参与者采取的各种策略预计将在预测期内提振市场。例如，2021 年 6 月，移植诊断公司 CareDx 收购了总部位于纽约的 Transplant Hero，这是一家旨在支持移植患者需求的智能手机应用程序开发商。由于主要市场参与者的这些努力，植入产品将变得更容易获得併帮助市场增长。

因此，上述所有因素都有望在预测期内提振市场。然而，器官捐献者短缺以及伦理和文化问题是预测期内市场的製约因素。

移植市场趋势

预计纸巾产品领域将在预测期内主导市场

组织捐赠是从一个人身上取出身体组织（皮肤、角膜、骨骼等）并将其移植到另一个人身上。该细分市场的扩张与移植手术的增加有关，例如人工耳蜗、心臟瓣膜、骨髓和矫形软组织。

根据 Organ Procurement Organization Association 2022 年 3 月的一份报告，每年约有 30,000 名组织捐献者为超过 175 万次挽救生命和挽救生命的组织移植做出贡献。因此，预计在预测期内增加组织移植将提振市场。

移植技术的进步和製造商推出的新产品预计将推动移植手术的数量，包括肾臟、肝臟、心臟、肺和组织移植。例如，2021 年 7 月，Bioventus Inc. 宣布推出 OSTEOAMP，这是一种流体同种异体移植骨替代解决方案，专为包括腰椎、颈椎和足/踝融合手术在内的多种患者手术而开发。推出了 SELECT Flowable。

此外，合作伙伴关係、併购正在支持市场的扩张。例如，2022 年 5 月，Orthofix Medical 与 MTF Biologics 续签并扩大了合作协议。该合作伙伴关係将 Orthofix 对 Trinity 同种异体移植线的独家商业权利扩展到 2032 年，还包括扩大协议以开发脱矿骨基质（ DBM ）， Orthofix 将以 Legacy 品牌名称销售。

因此，所有上述因素预计将在预测期内推动该部门的增长。

北美主导市场，预计在预测期内也会如此。

北美在移植诊断市场占有主要份额，预计在预测期内将保持相同的增长速度。

美国和加拿大等国家通过资金充足的机构、基础设施和政府参与创造了现金和意识，以鼓励患者进行器官移植。例如，根据美国国立卫生研究院2021年6月的数据，2018年、2019年和2020年用于移植研究的经费将分别达到6.5亿美元、7.33亿美元和7.21亿美元。据说有因此，增加对移植研究的资助将导致移植利用的增加，推动该地区的市场增长。

此外，根据卫生资源服务局的数据，到 2022 年 2 月，美国实体器官移植的国家移植等待名单上将有超过 106,000 人。实体器官移植候补名单的百分比为肾臟（83%）、肝臟（11%）、胰腺（1%）、心臟（3%）、肺（%）和其他（2%）。预计对实体器官的需求增加将导致对该细分市场的测试增加，从而在预测期内推动该细分市场的增长。根据2022年2月公布的器官捐献统计数据，2021年美国将进行4万多例器官移植。因此，在预测期内，移植的增加将推动该市场的增长。

预计慢性病患病率上升将在预测期内提振市场。美国癌症协会估计，到 2022 年，美国将有大约 79,000 例肾癌新病例，约有 13,920 人死于该病。根据同一消息来源，肾癌是男性和女性最常见的 10 种癌症之一。总体而言，男性一生中患肾癌的风险约为四分之一 (2.02%)。女性的终生风险约为 80 分之一 (1.03%)。

预计主要市场参与者增加产品发布将在预测期内提振市场。例如，2021 年 7 月，Orathofix Medical Inc. 推出并推出了首款带有 fiberFUSE Strip 的患者植入物，这是一种先进的脱矿纤维骨移植溶液，含有鬆质骨。

世界上很大一部分人口正在接近这两个国家以寻找更好的医疗保健设施，因此该地区非常有利于增长，并在预测期内研究的市场中占有很大份额。预计将占据

移植市场竞争者分析

市场高度分散，有许多大、中、小型供应商。併购帮助供应商扩展他们现有的产品组合和地理范围。参与者参与新产品发布、併购和区域扩张，以获取行业中最大的收入份额。该行业的主要参与者包括 Abbvie, Inc、Arthrex, Inc、Zimmer Biomet、Medtronic、Novartis AG 和 Strykers。

其他福利

  • Excel 格式的市场预测 (ME) 表
  • 3 个月的分析师支持

目录

第 1 章 简介

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第三章执行摘要

第四章市场动态

  • 市场概况
  • 市场驱动力
    • 慢性病负担加重
    • 增加器官衰竭的负担
    • 移植技术进步
  • 市场製约因素
    • 器官捐献者短缺
    • 伦理和文化问题
  • 波特五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争对手之间的竞争

第 5 章市场细分（基于价值的市场规模:百万美元）

  • 按产品
    • 纸巾产品
    • 免疫抑製剂
    • 保存液
  • 按申请
    • 器官移植
    • 组织移植
  • 按最终用户
    • 医院
    • 移植中心
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 欧洲其他地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 亚太其他地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 中东其他地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美地区

第六章竞争格局

  • 公司简介
    • Abbvie, Inc
    • Arthrex, Inc.
    • Zimmer Biomet
    • Medtronic
    • Novartis AG
    • Strykers
    • 21st Century Medicine
    • BiolifeSolutions, Inc
    • Teva Pharmaceuticals
    • Orthofix Medical
    • Veloxis Pharmaceutical
    • Amnio Technology

第七章市场机会与未来趋势

简介目录
Product Code: 90826

The Transplantation Market is expected to register a CAGR of 9.9% during the forecast period (2022-2027).

A major factor driving market growth is the rising demand for novel tissue transplantation products and organ transplantation to treat organ failure. According to the study published in Current Transplantation Reports, titled 'Diagnostic Testing of COVID-19 in Solid Organ Transplantation: Current Clinical Application and Future Strategies' in October 2020, multiple elements of solid organ transplantation have been impacted by the COVID-19 pandemic, including donor and recipient appropriateness, as well as infection and transmission prevention following transplantation. Moreover, according to the study titled "Epidemiology of Organ Failure Before and During COVID-19 Pandemic Surge Conditions," published in the American Journal of Critical Care in May 2022, during the pandemic, renal failure was the most common type of organ failure at admission and respiratory failure was the most common type of hospital-onset organ failure. The SARS-CoV-2-positive group showed a 231% increase in respiratory failure compared with the pre-pandemic group. Thus, with increasing organ failure, the demand for transplantation increases over the forecast period.

Moreover, the global demand for tissue and organ transplantation, particularly kidney, heart, liver, and lung transplantation, is extremely high. Organ failure is caused by a variety of factors, including poor dietary habits, excessive alcohol consumption, a lack of exercise, and drug abuse. As a result, transplantation product demand is expected to increase shortly. The rising donation of organs is one of the biggest contributors to the growth of the market studied. According to the data published by the Association of Organ Procurement Organizations (AOPO) in January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the previous year. The number of organs donated from dead donors increased to over 36,500 in 2020, an increase of almost 2% year over year. For the seventh year in a running, these retrieved organs saved more than 33,000 lives, exceeding the previous year's totals. There were also notable increases in Donation after Circulatory Death (DCD) contributions, which totaled more than 3,000 donors, up 18% year over year.

Furthermore, rising in the prevalence of chronic diseases such as cancer and heart and kidney diseases is propelling the growth of the market. For Instance, in March 2020, as per data released on World Kidney Day, a joint initiative of the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations (IFKF), kidney disease affected around 850 million people globally. In addition, as per the Globocan 2020 report published by Global Cancer Observatory, which estimated the incidence and mortality of 36 cancer in 185 countries globally, there were an estimated 19,292,789 new cases of cancer diagnosed in 2020, and about 9,958,133 people died due to cancer.

Additionally, product launches by the key market players, as well as various strategies adopted by the market players such as mergers and acquisitions, are anticipated to boost the market over the forecast period. For Instance, in June 2021, transplant diagnostics company CareDx acquired New York-based Transplant Hero, the developer of a smartphone app that's aimed at supporting the needs of transplant patients. As a result of such initiatives by key market players, the transplantation product becomes more accessible, boosting the market growth.

Thus, all aforementioned factors are anticipated to boost the market over the forecast period. However, the shortage of organ donors and ethical and cultural issues restraint the market over the forecast period,

Transplantation Market Trends

Tissue Product Segment is Expected to Dominate the Market Over the Forecast Period

Tissue donation is when tissues in the body (e.g., skin, corneas, bone) are removed from one person and transplanted into another person. The expansion of the segment is related to the increasing number of transplantation procedures such as cochlear, heart valves, bone marrow, and orthopedic soft tissues.

According to the Association of Organ Procurement Organization report in March 2022, Approximately 30,000 tissue donors contribute over 1.75 million life-saving and life-improving tissue transplants each year. Thus, increasing tissue transplantation is expected to boost the market over the forecast period.

Advancement in transplantation technology and the launch of new products by manufacturers is expected to propel the number of transplant procedures, including kidney, liver, heart, lungs, and tissues. For instance, in July 2021, Bioventus Inc. launched OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures, including lumbar spine fusion, cervical spine fusion, and foot & ankle fusion.

Furthermore, partnerships, mergers, and acquisitions are supporting market expansion. For instance, in May 2022, Orthofix Medical renewed and expanded its partnership agreement with MTF Biologics. The collaboration extends Orthofix's exclusive marketing rights to the Trinity allograft line through 2032 and includes an expansion agreement to develop a demineralized bone matrix (DBM) that Orthofix will market under the Legacy brand name.

Thus, all aforementioned factors are anticipated to boost the segment growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to hold a major share in the transplant diagnostics market and is expected to continue at the same pace over the forecast period.

Countries such as the United States and Canada have well-funded organizations, infrastructure, and government involvement in generating cash and creating awareness to encourage organ transplantation for patients. For instance, according to the National Institute of Health in June 2021, the fundings for the research in transplantation were USD 650 million, USD 733 million, and USD 721 million in 2018, 2019, and 2020 respectively. The rise in funding for transplantation research will therefore lead to increased utilization of transplants driving the growth of the market in this region.

Furthermore, according to the Health Resources and Services Administration, in February 2022, there will be over 106,000 people on the national transplant waiting list for solid organ transplantation in the United States. The percentage of people waiting for solid organ transplant includes Kidney (83%), liver (11%), Pancreas (1%), Heart (3%, Lung (%), and Others (2%). The rise in demand for solid organs will lead to increased testing for this segment, thereby expected to drive the growth of this segment over the forecast period. In addition, according to the Organ Donation Statistics published in February 2022, more than 40,000 organ transplantations have taken place in the United States in 2021. The rise in transplantations will therefore drive the growth of this market over the forecast period.

The rising prevalence of chronic diseases is anticipated to boost the market over the forecast period. According to the estimates of the American Cancer Society, in 2022, there were around 79,000 new cases of kidney cancer in the United States and approximately 13,920 deaths from this disease. As per the same source, kidney cancer is among the ten most common cancers in both men and women. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46 (2.02%). The lifetime risk for women is about 1 in 80 (1.03%).

Increasing product launches by the key market players are anticipated to boost the market over the forecast period. For instance, in July 2021, Orathofix Medical Inc. launched and first patient implants with the fiberFUSE Strip, an advanced demineralized fiber bone-graft solution containing cancellous bone.

With a large section of the population across the world approaching these two nations for better healthcare facilities, the region is expected to be very lucrative for growth and expected to hold a significant share in the market studied over the forecast period.

Transplantation Market Competitor Analysis

The market is highly fragmented, with the presence of many large, small, and medium-scale vendors. Mergers and acquisitions support vendors in expanding their existing product portfolio and geographical reach. The players are involved in launching new products, mergers & acquisitions, and regional expansion to gain maximum revenue share in the industry. Some of the major players in the industry are Abbvie, Inc., Arthrex, Inc., Zimmer Biomet, Medtronic, Novartis AG, and Strykers.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Chronic Diseases
    • 4.2.2 Increasing Burden of Organ Failure
    • 4.2.3 Technological Advancement in Transplantation Method
  • 4.3 Market Restraints
    • 4.3.1 Shortage of Organ Donors
    • 4.3.2 Ethical and Cultural Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Tissue Products
    • 5.1.2 Immunosuppressive Drugs
    • 5.1.3 Preservation Solution
  • 5.2 By Application
    • 5.2.1 Organ Transplantation
    • 5.2.2 Tissue Transplantation
  • 5.3 By End Use
    • 5.3.1 Hospitals
    • 5.3.2 Transplant Centers
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie, Inc
    • 6.1.2 Arthrex, Inc.
    • 6.1.3 Zimmer Biomet
    • 6.1.4 Medtronic
    • 6.1.5 Novartis AG
    • 6.1.6 Strykers
    • 6.1.7 21st Century Medicine
    • 6.1.8 BiolifeSolutions, Inc
    • 6.1.9 Teva Pharmaceuticals
    • 6.1.10 Orthofix Medical
    • 6.1.11 Veloxis Pharmaceutical
    • 6.1.12 Amnio Technology

7 MARKET OPPORTUNITIES AND FUTURE TRENDS